ARIAD publications
ARIAD scientists have published extensively on the role of cell signaling in disease, the design of drugs to inhibit cell signaling, and on the development and use of cell-signaling regulation technology. A listing of recent publications is provided below.
Publications on ARIAD’s product candidates
Ridaforolimus
- Mita M, Sankhala K, Abdel-Karim I, Mita A, Giles F. (2008) Deforolimus (AP23573) a novel mTOR inhibitor in clinical development. Expert Opin . Investig . Drugs. 17:1947-54.
- Hartford CM, Desai AA, Janisch L, Karrison T, Rivera VM, Berk L, Loewy JW, Kindler H, Stadler WM, Knowles HL, Bedrosian C, Ratain MJ. (2009) A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin Cancer Res. 15:1428-34.
- Mita MM, Mita AC, Chu QS, Rowinsky EK, Fetterly GJ, Goldston M, Patnaik A, Mathews L, Ricart AD, Mays T, Knowles H, Rivera VM, Kreisberg J, Bedrosian CL, Tolcher AW. (2008) Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol. 26:361-7.
- Rizzieri DA, Feldman E, Dipersio JF, Gabrail N, Stock W, Strair R, Rivera VM, Albitar M, Bedrosian CL, Giles FJ. (2008) A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 14:2756-62.
Cell-signaling inhibitors - research publications
- Wang Y, Shakespeare WC, Huang WS, Sundaramoorthi R, Lentini S, Das S, Liu S, Banda G, Wen D, Zhu X, Xu Q, Keats J, Wang F, Wardwell S, Ning Y, Snodgrass JT, Broudy MI, Russian K, Dalgarno D, Clackson T, Sawyer TK. (2008) Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitors. Bioorg Med Chem Lett. 18:4907-12.
- Shakespeare WC, Wang Y, Bohacek R, Keenan T, Sundaramoorthi R, Metcalf C 3rd, Dilauro A, Roeloffzen S, Liu S, Saltmarsh J, Paramanathan G, Dalgarno D, Narula S, Pradeepan S, van Schravendijk MR, Keats J, Ram M, Liou S, Adams S, Wardwell S, Bogus J, Iuliucci J, Weigele M, Xing L, Boyce B, Sawyer TK. (2008) SAR of carbon-linked, 2-substituted purines: synthesis and characterization of AP23451 as a novel bone-targeted inhibitor of Src tyrosine kinase with in vivo anti-resorptive activity. Chem Biol Drug Des. 71:97-105.
- Zhou T, Parillon L, Li F, Wang Y, Keats J, Lamore S, Xu Q, Shakespeare W, Dalgarno D, Zhu X. (2007) Crystal structure of the T315I mutant of AbI kinase. Chem Biol Drug Des. 70:171-81.
- Azam, M., Nardi, V., Latek, R.R., Shakespeare, W.C., Metcalf III, C.A., Bohacek, R.S., Wang, Y., Sundaramoorthi, R., Veach, D.R., Bornmann, W.G., Clarkson, B., Dalgarno, D.C., Sawyer, T.K., and Daley, G.Q., (2006) Activity of Dual SRC-ABL Inhibitors Highlights Role of BCR/ABL Kinase Dynamics in Drug Resistance. Proc. Natl. Acad. Sci. USA, 103: 9244-9249.
- Dalgarno, D., Stehle, T., Narula, S., Schelling, P., van Schravendijk, M., Adams, S., Andrade, L., Keats, J., Ram, M., Jin, L., Grossman, T., Metcalf III, C., Shakespeare, W., Wang, Y., Keenan, T., Sundaramoorthi, R. Bohacek, R., Weigele, M., and Sawyer, T.K., (2006) Structural Basis of Src Kinase Inhibition with a New Class of Potent and Selective Trisubstituted Purine-Based Compounds. Chem. Biol. Drug Design 67: 46-57.
ARGENT cell-signaling regulation technologies
More than 350 scientific publications have described the use of our Cell-signaling regulation technologies in diverse areas of biological research, including many papers authored by ARIAD scientists. A complete and annotated listing of these papers can be found in the Regulation Kits section of the website.
Publications relevant to ARIAD’s programs
ARIAD’s scientific programs have been validated through extensive publications in the scientific literature. Listed below are key scientific publications of relevance to our product candidates.
mTOR inhibition to treat solid tumors & other malignancies
- Mahalingam D, Sankhala K, Mita A, Giles FJ, Mita MM. (2009) Targeting the mTOR pathway using deforolimus in cancer therapy.Future Oncol.5:291-303.
- Guertin, D.A & Sabatini, D.M. (2005) An Expanding Role for mTOR in Cancer. Trends Mol. Med. 11:353-361.
- Dancey, J.E. (2005) Inhibitors of the Mammalian Target of Rapamycin. Expert Opin. Investig. Drugs 14:313-328.
Inhibition of Bcr/Abl to treat leukemia
- Quintás-Cardama A, Cortes J. (2008) Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia.Clin Cancer Res. 2008 Jul 15;14(14):4392-9.
- O'Hare T, Eide CA, Deininger MW. (2008) New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check Expert Opin Investig Drugs. 17:865-78.
- O'Hare T, Eide CA, Deininger MW. (2007) Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood. 110:2242-9.
Inhibition of ALK for cancer
- Thomas R Webb, Jake Slavish, Rani E George, A Thomas Look, Liquan Xue, Qin Jiang, Xiaoli Cui, Walter B Rentrop and Stephan W Morris (2009) Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy Expert Review of Anticancer Therapy 9, 331-356
- Roberto Chiarle, Claudia Voena, Chiara Ambrogio, Roberto Piva & Giorgio Inghirami (2008) The anaplastic lymphoma kinase in the pathogenesis of cancer. Nature Reviews Cancer 8, 11-23
- Manabu Soda, Young Lim Choi, Munehiro Enomoto, Shuji Takada, Yoshihiro Yamashita, Shunpei Ishikawa, Shin-ichiro Fujiwara, Hideki Watanabe, Kentaro Kurashina, Hisashi Hatanaka, Masashi Bando, Shoji Ohno, Yuichi Ishikawa, Hiroyuki Aburatani, Toshiro Niki, Yasunori Sohara, Yukihiko Sugiyama & Hiroyuki Mano (2007) Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer Nature 448, 561-566
Kinase inhibitors for cancer
- Jianming Zhang, Priscilla L. Yang & Nathanael S. Gray (2009) Targeting cancer with small molecule kinase inhibitors Nature Reviews Cancer 9, 28-39
- Jack A. Bikker, Natasja Brooijmans, Allan Wissner and Tarek S. Mansour (2009) Kinase Domain Mutations in Cancer: Implications for Small Molecule Drug Design Strategies J. Med. Chem.52, 1493–1509
The inclusion of external links does not imply endorsement of the content of the external site by us. We have no control over the content of these sites and assume no responsibility or liability for this third-party content.
